Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02960074
Recruitment Status : Active, not recruiting
First Posted : November 9, 2016
Last Update Posted : August 13, 2020
Sponsor:
Information provided by (Responsible Party):
Rima Rachid, Boston Children’s Hospital

Brief Summary:
This is a Phase I trial to evaluate the safety and efficacy of oral encapsulated fecal microbiota transplantation (FMT) in the treatment of peanut allergy. In this research the investigators would like to learn more about ways to treat peanut allergies. There is currently no known cure for peanut allergy. The primary aim is to assess safety and tolerability of oral FMT in patients with peanut allergy aged 18-40 years.

Condition or disease Intervention/treatment Phase
Peanut Allergy Biological: Fecal Microbiota Capsule Phase 1

Detailed Description:
This is a study of fecal microbiota transplantation (FMT) in the treatment of peanut allergy. The primary aim is to assess safety and tolerability of oral encapsulated FMT in patients with peanut allergy aged 18-40 years. A total of 15 patients with peanut allergy will be enrolled after they fail a screening food challenge to peanut. 10 patients will be given oral encapsulated frozen FMT over 1-2 days. 5 additional patients will receive antibiotics prior to being given oral encapsulated frozen FMT over 1-2 days. Patients will undergo a second and third food challenge after receiving FMT. The expected duration of the study for each subject will be one year. Stool collection, skin testing and blood samples will be done serially.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open Label Trial to Evaluate the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplantation in Peanut Allergic Patients
Actual Study Start Date : March 3, 2017
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Non-antibiotics Arm
The first 10 patients will not receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
Biological: Fecal Microbiota Capsule
We will treat patients with oral encapsulated frozen FMT over 2 days.
Other Names:
  • FMT Therapy
  • Fecal Microbiota Transplant

Experimental: Antibiotics Arm
An additional 5 patients will receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
Biological: Fecal Microbiota Capsule
We will treat patients with oral encapsulated frozen FMT over 2 days.
Other Names:
  • FMT Therapy
  • Fecal Microbiota Transplant




Primary Outcome Measures :
  1. Presence of FMT-related adverse events grade 2 or above [ Time Frame: 12 months ]
    Presence of FMT-related adverse events grade 2 or above


Secondary Outcome Measures :
  1. Changes in threshold of peanut reactivity during a double blind placebo controlled food challenge from 100 mg to 300 mg peanut protein, using PRACTALL guidelines [ Time Frame: 1 day ]
    To evaluate whether FMT therapy alone or after antibiotic pretreatment can increase the threshold of peanut sensitivity during a double blind placebo controlled food challenge from 100 mg peanut protein to 300 mg.

  2. Changes in threshold of peanut reactivity from 100 mg to 600 mg peanut protein during double blind placebo controlled food challenge using PRACTALL guidelines [ Time Frame: 1 day ]
    To evaluate whether FMT therapy alone or after antibiotic pretreatment can increase the threshold of peanut sensitivity during a double blind placebo controlled food challenge from 100 mg peanut protein to 600 mg

  3. Changes in skin test peanut specific wheal size in mm [ Time Frame: 12 months ]
    To evaluate the changes following FMT (with and without antibiotics), to peanut specific skin prick test.

  4. Changes in serum peanut-specific IgE level in kU/L [ Time Frame: 12 months ]
    To evaluate the changes following FMT (with and without antibiotics), to serum peanut-specific IgE level in kU/L

  5. Changes in gut microbial composition measured in serial stool samples, using 16S RNA sequencing and persistence of that change over time [ Time Frame: 12 months ]
    To evaluate the changes following FMT (with and without antibiotics), to gut microbial composition measured in serial stool samples, using 16S RNA sequencing and persistence of that change over time



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Develop dose limiting symptoms to peanut during a DPBCFC conducted in accordance with PRACTALL (Practical Issues in Allergology, Joint United States/European Union Initiative) guidelines at 3 mg, 10 mg, 30 mg, or 100 mg peanut protein.
  2. Has a positive SPT to peanut (≥5mm) and/or a positive peanut-specific IgE >0.35kU/L.
  3. Has a Spirometry or Peak Flow with Measurement of FEV1>=80% of predicted
  4. Have negative test results for Hepatitis B surface antigen and antibodies (HBV), Hepatitis C (HCV), and Human Immunodeficiency Virus (HIV).
  5. Have a negative urine hCG test if a female participant.
  6. Agrees to use an acceptable single-barrier form of birth control from enrollment through the 4 month DBPCFC study visit if female of childbearing potential if sexually active. An example of a single-barrier method of contraception includes condoms or oral contraceptives. Acceptable methods of birth control include implants, injectables, combined oral contraceptives, some intrauterine contraceptive devises (IUDs), sexual abstinence, a vasectomized partner, the contraceptive patch, the contraceptive ring, and condoms.
  7. Able to swallow 2 empty capsules size 00.
  8. Able to give informed consent.
  9. Willing and able to participate in the study requirements, including study visits, DBPCFCs, serial stool collection
  10. Willing to undergo telephone follow-up to assess for safety and adverse events.

Exclusion Criteria:

  1. Patients with a history of severe anaphylaxis to peanut and/or treenuts (hypotension requiring vasopressor support, hypoxia requiring mechanical ventilation, or neurological compromise and/or ICU admission)
  2. Patients with other food allergies (i.e. IgE mediated food restrictions not including oral allergy syndrome) excluding peanut and tree nuts.
  3. Patients with Bovine gelatin allergy.
  4. Patients with chronic illness other than controlled asthma that is mild intermittent, mild- persistent or moderate persistent, mild eczema and allergic rhinitis. Exceptions can be made per PI discretion if illness is not expected to affect allergies or treatment.
  5. Recurrent or chronic infections necessitating frequent systemic (including oral) antibiotic administration.
  6. History of chronic immunosuppressive therapies.
  7. Patients who are diagnosed with active, chronic urticaria.
  8. Patients who have received a dose of peanut oral immunotherapy within the last year, Patients on aeroallergen immunotherapy maintenance therapy for less than 6 months, or patients who have received Omalizumab therapy within the last year.
  9. Women who are pregnant or breast feeding, or planning to get pregnant during the time of the study.
  10. Sexually active female patients who refuse to use contraception from enrollment through the 4 month DBPCFC study visit
  11. Patient with GI conditions including inflammatory bowel disease eosinophilic esophagitis, food protein induced enterocolitis, uncontrolled reflux despite medication, uncontrolled chronic constipation despite medication, esophageal dysmotility, swallowing dysfunction, delayed gastric emptying syndromes, pill esophagitis or history of aspiration pneumonia within 3 months prior to screening.
  12. Patient with current or a history of rheumatologic conditions. Exceptions can be made per PI discretion if illness is not expected to affect allergies or treatment.
  13. Patients who have a direct relative (biologic parent or sibling) with inflammatory bowel disease.
  14. Patients with any form of immunodeficiency.
  15. Patients participating or planning to participate in the next 6 months. Exceptions can be made per PI discretion.
  16. Patients with positive antibody test results for HBV, HCV, or HIV.
  17. Patients who have received systemic corticosteroids therapy for 1 week or more over the past 3 months.
  18. Patients who develop dose limiting symptoms to peanut during a DPBCFC conducted in accordance with PRACTALL guidelines at 1 mg peanut protein.
  19. Patient with an allergy to Vancomycin, Neomycin or metronidazole (for those who will receive antibiotic pre-treatment)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02960074


Locations
Layout table for location information
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Rima Rachid
Investigators
Layout table for investigator information
Principal Investigator: Rima Rachid, MD Boston Children’s Hospital
Layout table for additonal information
Responsible Party: Rima Rachid, Attending Physician, Division of Immunology, Boston Children’s Hospital
ClinicalTrials.gov Identifier: NCT02960074    
Other Study ID Numbers: P00020640
First Posted: November 9, 2016    Key Record Dates
Last Update Posted: August 13, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Rima Rachid, Boston Children’s Hospital:
Allergy, Peanut
Hypersensitivity Peanut
Peanut Allergy
Donor Feces Infusion
Fecal Transplant
Fecal Transplantation
Intestinal Microbiota Transfer
Fecal Microbiota Transplantation
Food allergy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypersensitivity
Peanut Hypersensitivity
Immune System Diseases
Nut and Peanut Hypersensitivity
Food Hypersensitivity
Hypersensitivity, Immediate